<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35231">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023320</url>
  </required_header>
  <id_info>
    <org_study_id>eki-842</org_study_id>
    <nct_id>NCT02023320</nct_id>
  </id_info>
  <brief_title>Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Blueberry Dry Powder on Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agricultural Producers' Cooperative Corporation Shinpo-en</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hiroshima University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the effect of blueberry dry powder on
      glycemic status (fasting plasma glucose, 2h glucose concentration after the oral glucose
      tolerance test (OGTT), or HbA1c) in subjects with prediabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in fasting plasma glucose from baseline</measure>
    <time_frame>Every 6 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycoalbumin from baseline</measure>
    <time_frame>Every 6 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting insulin from baseline</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in homeostasis model assessment-insulin resistance (HOMA-R) from baseline</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>HOMA-R is calculated as fasting insulin (mU/mL) x fasting glucose (mg/dL) / 405</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-peptide from baseline</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Low dose of blueberry dry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 g blueberry dry powder, twice a day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of blueberry dry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 g blueberry dry powder, twice a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low dose of blueberry dry powder</intervention_name>
    <arm_group_label>Low dose of blueberry dry powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High dose of blueberry dry powder</intervention_name>
    <arm_group_label>High dose of blueberry dry powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting plasma glucose 110-125 mg/dL

        Exclusion Criteria:

          -  Taking anti-diabetic drugs

          -  Taking drugs or functional food that may affect blood glucose level

          -  Fruit allergy

          -  Pregnant or nursing a child

          -  Participation in any clinical trial within 90 days of the commencement of the trial

          -  Renal or hepatic dysfunction

          -  Heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fumiko Higashikawa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fumiko Higashikawa, PhD</last_name>
    <phone>+81-82-257-1533</phone>
    <email>fumiko@hiroshima-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumiko Higashikawa, PhD</last_name>
      <email>fumiko@hiroshima-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hiroshima University</investigator_affiliation>
    <investigator_full_name>Fumiko Higashikawa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
